Sign in

UTHR on Nasdaq

UNITED THERAPEUTICS Corp

UNITED THERAPEUTICS Corp is an American pharmaceutical preparations company, incorporated in Delaware.1 It is headquartered in Silver Spring, Maryland.1 Its shares trade on Nasdaq under the symbol UTHR.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with BioMarin Pharmaceutical, Amneal Pharmaceuticals, Inc. or Alnylam Pharmaceuticals, or pick any stock.

  • TickerUTHR on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersSilver Spring, Maryland1
  • Incorporated inDE2
  • Business address1000 Spring St, Silver Spring, Md 209102
  • Filer categoryLarge accelerated filer2

See how the biggest companies compare on our leaderboards

Founded by our Chairperson and Chief Executive Officer, Martine Rothblatt, to find a cure for her daughter’s life-threatening rare disease, pulmonary arterial hypertension ( PAH ), United Therapeutics advances therapies for people living with serious diseases with unmet medical needs. Our mission is to transform the treatment of rare diseases and expand the availability of transplantable organs through innovative organ manufacturing technologies.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

87.9%Gross margin5
46.9%Operating margin5
41.9%Net margin5
10.6%Revenue growth, 20255
18.8%Return on equity5
$1.0BFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Tyvaso DPI brought in 41% of the revenue UNITED THERAPEUTICS Corp broke down this way in fiscal 2025.

  1. Tyvaso DPI$1.3B541%up 25% from 2024
  2. Nebulized Tyvaso$585.7M518%down 0% from 2024
  3. Remodulin$526.8M517%down 2% from 2024
  4. Orenitram$496.9M516%up 14% from 2024
  5. Unituxin$226.8M57%down 5% from 2024
  6. Adcirca$30.0M51%up 26% from 2024
  7. Product and Service, Other$24.0M51%up 9% from 2024
Products and services by year
Products and services202320242025
Tyvaso DPI$731.1M$1.0B$1.3B
Nebulized Tyvaso$502.6M$586.8M$585.7M
Remodulin$494.8M$538.1M$526.8M
Orenitram$359.4M$434.3M$496.9M
Unituxin$198.9M$238.7M$226.8M
Adcirca$28.9M$23.8M$30.0M
Product and Service, Other$11.8M$22.1M$24.0M

Regions

United States brought in 95% of the revenue UNITED THERAPEUTICS Corp broke down this way in fiscal 2025.

  1. United States$3.0B595%up 11% from 2024
  2. Outside the United States$145.7M55%up 6% from 2024
Regions by year
Regions202320242025
United States$2.2B$2.7B$3.0B
Outside the United States$125.3M$137.7M$145.7M

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue11¢$384.4M
  • Research and development16¢$550.0M
  • Selling, general and admin22¢$755.8M
  • Income tax11¢$379.2M
  • Profit39¢$1.3B

Out of $3.2B in revenue.5

Where each dollar of operating cash went, fiscal 2025

  • Capital spending33¢$520.5M
  • Share buybacks64¢$1.0B
  • Kept or used elsewhere3¢$40.7M

Out of $1.6B of cash from operations.5

Financial statements

Revenue67895$3.2B in 2025+120% since 2019
0$1.0B$2.0B$3.0B$4.0B2019: $1.4B$1.4B20192020: $1.5B$1.5B2020+2%2021: $1.7B$1.7B2021+14%2022: $1.9B$1.9B2022+15%2023: $2.3B$2.3B2023+20%2024: $2.9B$2.9B2024+24%2025: $3.2B$3.2B2025+11%
Gross profit67895$2.8B in 2025+110% since 2019
0$1.0B$2.0B$3.0B2019: $1.3B$1.3B20192020: $1.4B$1.4B2020+3%2021: $1.6B$1.6B2021+14%2022: $1.8B$1.8B2022+14%2023: $2.1B$2.1B2023+16%2024: $2.6B$2.6B2024+24%2025: $2.8B$2.8B2025+9%
Operating income67895$1.5B in 2025
-$500.0M0$500.0M$1.0B$1.5B2019: -$187.6M-$187.6M20192020: $593.6M$593.6M20202021: $555.9M$555.9M2021−6%2022: $979.7M$979.7M2022+76%2023: $1.2B$1.2B2023+21%2024: $1.4B$1.4B2024+16%2025: $1.5B$1.5B2025+8%
Net income10895$1.3B in 2025
-$500.0M0$500.0M$1.0B$1.5B2019: -$104.5M-$104.5M20192021: $475.8M$475.8M20212022: $727.3M$727.3M2022+53%2023: $984.8M$984.8M2023+35%2024: $1.2B$1.2B2024+21%2025: $1.3B$1.3B2025+12%

Every line of the income statement as filed: the last 3 fiscal years, latest first.5

Period ending2025-12-312024-12-312023-12-31
Total revenues$3.2B$2.9B$2.3B
Cost of sales$384.4M$309.7M$257.5M
Research and development$550.0M$481.0M$408.0M
Selling, general, and administrative$755.8M$709.7M$477.1M
Total operating expenses$1.7B$1.5B$1.1B
Operating income$1.5B$1.4B$1.2B
Interest income$192.0M$199.1M$162.7M
Interest expense-$19.5M-$42.9M-$59.3M
Other income (expense), net$48.9M$5.8M-$14.0M
Total other income, net$221.4M$162.0M$89.4M
Income before income taxes$1.7B$1.5B$1.3B
Income tax expense-$379.2M-$343.9M-$289.5M
Net income$1.3B$1.2B$984.8M
Basic (in dollars per share)$30.13$26.44$21.04
Diluted (in dollars per share)$27.86$24.64$19.81
Basic (in shares)44.3M shares45.2M shares46.8M shares
Diluted (in shares)47.9M shares48.5M shares49.7M shares

Compare UNITED THERAPEUTICS Corp with another company

Corporate structure

UNITED THERAPEUTICS Corp sits at the top of its group. 7 entities, 4 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of UNITED THERAPEUTICS Corp

  • Martine A. Rothblatt Filed SCHEDULE 13G/A on UNITED THERAPEUTICS Corp, latest Aug 14, 2026 (5 filings since Feb 4, 2022)
  • Wellington Management Company Filed SCHEDULE 13G/A on UNITED THERAPEUTICS Corp, latest Aug 13, 2026 (7 filings since Feb 6, 2023)
  • VANGUARD CAPITAL MANAGEMENT LLC Filed SCHEDULE 13G on UNITED THERAPEUTICS Corp, latest Apr 30, 2026
  • VANGUARD GROUP INC Filed SCHEDULE 13G/A on UNITED THERAPEUTICS Corp, latest Mar 27, 2026 (5 filings since Feb 10, 2022)
  • State Street Corporation Filed SCHEDULE 13G on UNITED THERAPEUTICS Corp, latest Feb 5, 2025 (2 filings since Oct 16, 2024)
  • Avoro Capital Advisors LLC Filed SC 13G/A on UNITED THERAPEUTICS Corp, latest Feb 14, 2024 (3 filings since Feb 11, 2022)
  • RENAISSANCE TECHNOLOGIES LLC Filed SC 13G/A on UNITED THERAPEUTICS Corp, latest Feb 13, 2024 (3 filings since Feb 11, 2022)
  • FMR LLC Filed SC 13G/A on UNITED THERAPEUTICS Corp, latest Feb 9, 2024 (3 filings since Feb 9, 2022)
  • BlackRock Filed SC 13G/A on UNITED THERAPEUTICS Corp, latest Jan 24, 2024 (4 filings since Feb 3, 2022)
  • Celularity Operations Inc. Filed SC 13G/A on UNITED THERAPEUTICS Corp, latest Feb 3, 2023 (2 filings since Feb 4, 2022)
  • UNITED THERAPEUTICS Corp Silver Spring, Maryland
    • Celularity Inc Stake · Florham Park, New Jersey
    • Clene Inc. Stake · Salt Lake City, Utah
    • Miromatrix Medical Inc. Stake · Eden Prairie, Minnesota
    • United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Subsidiary · United Kingdom
    • United Therapeutics Ireland Limited, a company incorporated under the laws of Subsidiary · Ireland
    • United Therapeutics Netherlands B.V., a company incorporated under the laws of Subsidiary · Netherlands

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (3 companies). Each entity in the chart links to its source.

What it owns

What UNITED THERAPEUTICS Corp reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$2.3B5 Dec 31, 2025$1.7B5 Dec 31, 2024+34.1%
Accumulated depreciation$567.8M5 Dec 31, 2025$491.2M5 Dec 31, 2024+15.6%
Property and equipment, net$1.7B5 Dec 31, 2025$1.2B5 Dec 31, 2024+41.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.6B5 Dec 31, 2025$1.7B5 Dec 31, 2024−8.3%
Marketable securities, current$1.4B5 Dec 31, 2025$1.6B5 Dec 31, 2024−13.2%
Marketable securities, non-current$1.8B5 Dec 31, 2025$1.5B5 Dec 31, 2024+20.4%
Equity securities at fair value$126.9M5 Dec 31, 2025$23.9M5 Dec 31, 2024+431.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$32.3M5 Dec 31, 2025$32.3M5 Dec 31, 20240%
Accumulated amortization$7.8M5 Dec 31, 2025$6.9M5 Dec 31, 2024+13.0%

Inventory

ItemLatestA year beforeChange
Inventory, total$183.1M5 Dec 31, 2025$157.9M5 Dec 31, 2024+16.0%
Raw materials$30.6M5 Dec 31, 2025$28.6M5 Dec 31, 2024+7.0%
Work in process$35.3M5 Dec 31, 2025$34.3M5 Dec 31, 2024+2.9%
Finished goods$117.2M5 Dec 31, 2025$95.0M5 Dec 31, 2024+23.4%

Properties, in its own words

North Carolina—We own a total of 279 acres and have active operations in approximately 630,000 square feet at our co-headquarters campus in RTP. Our clinical research and development, commercialization, manufacturing, warehousing and logistics hub, and our ULobe research and development laboratory, all operate within this campus. We manufacture Orenitram drug product and we package, warehouse, and distribute Nebulized Tyvaso, Tyvaso DPI, Remodulin, Orenitram, and Unituxin at this location. If the FDA approves ralinepag, we plan to transfer manufacturing of this product to our RTP campus following commercial launch. We also have an additional capacity for future growth and expansion at this campus. Additionally, we lease approximately 21,000 square feet of office space in Morrisville, North Carolina to house our United Therapeutics Cares patient support program.

Maryland—We own a 415,000 square foot combination laboratory and office building campus in Silver Spring, Maryland that serves as our co-headquarters, is used to manufacture certain of our products, and houses one of our ex vivo lung perfusion centers. Manufacturing activities at this campus include the synthesis of treprostinil, the active ingredient in Tyvaso DPI, Nebulized Tyvaso, and Remodulin, and treprostinil diolamine, the active ingredient in Orenitram, as well as dinutuximab, the active ingredient in Unituxin. We also manufacture Nebulized Tyvaso drug product, Remodulin drug product, and Unituxin drug product at our Silver Spring campus. We plan to produce manufactured lung alternatives for clinical studies at our Silver Spring campus.

The rest of Item 2

Minnesota—Our Miromatrix subsidiary leases a 42,300 square foot office and laboratory facility in Eden Prairie, Minnesota, where it produces manufactured kidney and liver products for research and development purposes and clinical trials. We are constructing a 65,000 square foot clinical-scale DPF facility in Stewartville, Minnesota where we intend to produce porcine hearts and kidneys for use in xenotransplantation clinical trials and to support eventual commercial production of our xeno-organs following FDA approval.

Florida—We own a 75,000 square foot building on land we lease on the Mayo Clinic campus in Jacksonville, Florida, which houses one of our ex vivo lung perfusion centers. We also own a 14,000 square foot building in Melbourne, Florida, which houses a call center.

New Hampshire—We lease a 74,500 square foot office and laboratory facility in Manchester, New Hampshire, where we conduct our 3D organ alternative bioprinting research and development activities.

48 · United Therapeutics, a public benefit corporation

Texas—We are constructing a 65,000 square foot clinical scale DPF facility in Houston, Texas, where we intend to produce porcine hearts and kidneys for use in xenotransplantation clinical trials, and to support eventual commercial production of our xeno-organs following FDA approval.

Virginia—We own and operate a 65,000 square foot clinical-scale DPF facility in Christiansburg, Virginia where we produce porcine hearts and kidneys for use in xenotransplantation clinical trials, and where we intend to support eventual commercial production of our xeno-organs following FDA approval. We also lease a laboratory and farm in Blacksburg, Virginia that support our xenotransplantation research and development efforts.

Quebec—We own a 23,000 square foot facility in Bromont, Quebec, Canada, which is dedicated to the development of sustainable aircraft for the delivery of manufactured organs and organ alternatives.

Massachusetts—Our IVIVA subsidiary leases a 23,500 square foot office and laboratory facility in Medford, Massachusetts, where it produces manufactured kidney alternative products for research and development purposes and clinical trials. In 2025, we purchased a 50,000 square foot facility in Lexington, Massachusetts, which is intended to serve as a cGMP site for clinical production of manufactured organs.

We believe that these facilities, along with various other owned and leased facilities, are adequate for our current operations and that additional land and facilities for future expansion are reasonably available.

Item 2 of the 10-K filed Feb 25, 2026.4

Leadership

Who has led UNITED THERAPEUTICS Corp, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Roger Jeffs2015–2016

President

  1. Roger Jeffs2006–2016
  2. Michael Benkowitz2016–now

Chief financial officer

  1. Fred T. Hadeed2006
  2. Paul A. Mahon2006
  3. John Maxim Ferrari2006–2015
  4. James Edgemond2015–now

Chief operating officer

  1. Roger Jeffs2006–2014
  2. David Zaccardelli2015–2016
  3. Michael Benkowitz2016–now
2010201520202025
Board members and other officers (18)

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • United Therapeutics Europe, Ltd., a company incorporated under the laws of England and Wales3
  • United Therapeutics Ireland Limited, a company incorporated under the laws of Ireland3
  • United Therapeutics Netherlands B.V., a company incorporated under the laws of the Netherlands3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Oct 14, 20268-K Other events39
  2. Sep 8, 20268-K Entered a material agreement; Regulation FD disclosure40
  3. Aug 5, 20268-K Results of operations41
  4. Jul 23, 20268-K Executive or director change; Regulation FD disclosure42
  5. Jun 29, 20268-K Executive or director change; Shareholder vote43
  6. May 6, 20268-K Results of operations44
  7. Mar 30, 20268-K Other events45
  8. Mar 9, 20268-K Entered a material agreement; Regulation FD disclosure46
  9. Mar 2, 20268-K Regulation FD disclosure47
  10. Feb 25, 20268-K Results of operations48
  11. Jan 22, 20268-K Executive or director change; Bylaws or fiscal year changed; Regulation FD disclosure49
  12. Oct 29, 20258-K Results of operations50
  13. Jan 2, 2015New chief executive Roger Jeffs becomes CEO14

Calendar

Coming up

  1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported $7.16 a share, on Oct 29, 2025.51

When it reported results

  1. Aug 5, 2026Reported quarterly or annual results41
  2. May 6, 2026Reported quarterly or annual results44
  3. Feb 25, 2026Reported quarterly or annual results48
  4. Oct 29, 2025Reported quarterly or annual results50
  5. Jul 30, 2025Reported quarterly or annual results52
  6. Apr 30, 2025Reported quarterly or annual results53
  7. Feb 26, 2025Reported quarterly or annual results54
  8. Oct 30, 2024Reported quarterly or annual results55

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

1,230 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 56 major events, 822 insider forms, 35 large holders, 297 other. The latest 20:

  1. Oct 15, 2026144 EDGAR
  2. Oct 15, 20264 PRIMARY DOCUMENT EDGAR
  3. Oct 14, 20264 PRIMARY DOCUMENT EDGAR
  4. Oct 14, 20268-K EDGAR
  5. Oct 13, 20264 PRIMARY DOCUMENT EDGAR
  6. Oct 13, 20264 PRIMARY DOCUMENT EDGAR
  7. Oct 9, 20264 PRIMARY DOCUMENT EDGAR
  8. Oct 8, 20264 PRIMARY DOCUMENT EDGAR
  9. Oct 7, 20264 PRIMARY DOCUMENT EDGAR
  10. Oct 6, 20264 PRIMARY DOCUMENT EDGAR
  11. Oct 5, 20264 PRIMARY DOCUMENT EDGAR
  12. Oct 2, 20264 PRIMARY DOCUMENT EDGAR
  13. Oct 1, 2026144 EDGAR
  14. Oct 1, 2026144 EDGAR
  15. Oct 1, 20264 PRIMARY DOCUMENT EDGAR
  16. Oct 1, 20264 PRIMARY DOCUMENT EDGAR
  17. Oct 1, 20264 PRIMARY DOCUMENT EDGAR
  18. Sep 30, 20264 PRIMARY DOCUMENT EDGAR
  19. Sep 29, 20264 PRIMARY DOCUMENT EDGAR
  20. Sep 28, 20264 PRIMARY DOCUMENT EDGAR

The 1,230 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

793 open-market trades by officers, directors and large owners since October 2021: 1 buys and 792 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 29, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$477.42$4.5MForm 4
Sep 28, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$480.85$4.6MForm 4
Sep 25, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$476.17$4.5MForm 4
Sep 24, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$473.55$4.5MForm 4
Sep 23, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$491.57$4.7MForm 4
Sep 22, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$494.83$4.7MForm 4
Sep 21, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$494.55$4.7MForm 4
Sep 18, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$494.79$4.7MForm 4
Sep 17, 2026MAHON PAUL AEVP & GENERAL COUNSELSale8,300$497.54$4.1MForm 4
Sep 17, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$496.06$4.7MForm 4
Sep 16, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$501.39$4.8MForm 4
Sep 15, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$501.59$4.8MForm 4
Sep 14, 2026Mesa NildaDirectorSale228$505.87$115.3KForm 4
Sep 14, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$504.12$4.8MForm 4
Sep 11, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$500.82$4.8MForm 4
Sep 10, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$502.35$4.8MForm 4
Sep 9, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$501.84$4.8MForm 4
Sep 8, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$499.03$4.7MForm 4
Sep 4, 2026ROTHBLATT MARTINE AChairperson & CEOSale9,500$489.20$4.6MForm 4
Sep 3, 2026MAHON PAUL AEVP & GENERAL COUNSELSale8,300$482.03$4.0MForm 4

All 793 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

UNITED THERAPEUTICS Corp has told the SEC it owns more than 5% of 3 companies, latest first (Schedules 13D and 13G).

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Martine RothblattChairperson and Chief Executive Officer$1.5M$18.0M69
2025Michael BenkowitzPresident and Chief Operating Officer$1.4M$14.4M69
2025James EdgemondChief Financial Officer and Treasurer$955.8K$8.3M69
2025Paul MahonExecutive Vice President and General Counsel$964.2K$5.5M69
2024Martine RothblattChairperson and Chief Executive Officer$1.5M$23.0M69
2024Michael BenkowitzPresident and Chief Operating Officer$1.2M$13.9M69
2024James EdgemondChief Financial Officer and Treasurer$860.6K$9.2M69
2024Paul MahonExecutive Vice President and General Counsel$940.0K$7.0M69
2023Martine RothblattChairperson and Chief Executive Officer$1.5M$17.0M69
2023Michael BenkowitzPresident and Chief Operating Officer$1.1M$9.8M69
2023James EdgemondChief Financial Officer and Treasurer$790.4K$6.1M69
2023Paul MahonExecutive Vice President and General Counsel$940.0K$5.2M69

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.5,294,529$2.9B0.0%−105,120
Avoro Capital Advisors LLC2,777,777$1.5B13.5%+147,777
Vanguard Portfolio Management LLC1,919,429$1.0B0.0%−84,313
Vanguard Capital Management LLC1,918,256$1.0B0.0%−39,283
State Street Corp1,898,064$1.0B0.0%+54,101
Renaissance Technologies LLC1,708,739$925.8M1.3%−78,280
Wellington Management Group Llp1,379,025$747.2M0.1%−885,222
Geode Capital Management, LLC996,598$538.9M0.0%−236,431
Jupiter Topco LLC831,129$450.1M0.2%New
Norges Bank694,753$376.4M0.0%New
Assetmark, Inc624,068$338.1M0.6%+8,018
Aqr Capital Management LLC546,002$294.6M0.1%−280,224
Dimensional Fund Advisors LP527,904$286.0M0.1%+15,165
Fmr LLC473,409$256.5M0.0%−54,937
Invesco Ltd.473,109$256.3M0.0%−135,258
Baillie Gifford & Co467,209$253.1M0.2%+39,082
Deerfield Management Company, L.P.457,000$247.6M3.1%No change
Morgan Stanley436,699$236.6M0.0%+27,411
Vestal Point Capital, LP435,000$235.7M5.5%+360,000
Northern Trust Corp430,844$233.4M0.0%−5,722
Millennium Management LLC409,074$221.6M0.2%+255,702
Franklin Resources Inc340,275$184.4M0.0%+62,292
Swedbank AB322,995$175.0M0.2%−4,127
Citadel Advisors LLC304,692$165.1M0.1%−55,951
Charles Schwab Investment Management Inc297,162$161.0M0.0%−3,319

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

5 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
Oct 31, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000−8.4%Report
Oct 30, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000+5.9%Report
Oct 30, 2025Lisa C. McClainRepublican, HouseSale$1,001 - $15,000−5.9%Report
Jun 11, 2025Lisa C. McClainRepublican, HouseBuy$1,001 - $15,000+67.5%Report
Mar 6, 2019Donna Shalala, HouseSale$1,001 - $15,000−208.7%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How UNITED THERAPEUTICS Corp is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARUNITED THERAPEUTICS Corp1
  • CIK0001082554
  • Employer ID (EIN)52-19847494
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address1000 Spring St, Silver Spring, MD 209101
  • Phone30160892921
  • Shares outstanding42,890,692 as of Jul 29, 202612
  • Public float$11.2B as of Jun 30, 20254
  • AuditorErnst & Young LLP, Tysons, Virginia PCAOB ID 42; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceApr 16, 19991
  • Filings4,395 in all: 4 (3,170), 8-K (334), 144 (250), SC 13G/A (143), 10-Q (82), SC 13G (69), 4/A (52), DEF 14A (28)1
    All 44 form types

    10-K (26), UPLOAD (26), DEFA14A (21), S-8 (21), 3 (18), CORRESP (18), CT ORDER (14), SD (13), ARS (12), POS AM (10), S-8 POS (10), 8-K/A (8), S-3/A (8), 424B7 (7), S-3 (6), S-1/A (5), SCHEDULE 13G/A (5), 424B3 (4), 424B1 (3), PRE 14A (3), SC 13D (3), SC TO-C (3), SC TO-T/A (3), SCHEDULE 13G (3), 8-A12G (2), 8-A12G/A (2), EFFECT (2), S-1 (2), SC TO-I/A (2), 10-K/A (1), 10-K405 (1), NO ACT (1), S-3ASR (1), S-4 (1), SC TO-I (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) Feb 25, 2026
    Quarterly report (10-Q) Aug 5, 2026
    Proxy statement (DEF 14A) Apr 29, 2026
    Latest 8-K (8-K) Oct 14, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $.01 per shareUTHRNasdaq Global Select Market

From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks UNITED THERAPEUTICS Corp names in Item 1A of its 10-K filed Feb 25, 2026: 32 risks under these headings, as written.4

  • We rely heavily on sales of our treprostinil-based therapies to generate revenues and support our operations.
  • If our products fail in clinical trials, we will be unable to sell those products.
  • We may not compete successfully with established or newly developed drugs or products.
  • The successful commercialization of our products depends on the availability of coverage and adequacy of reimbursement from third-party payers, including governmental authorities and private health insurers. Pharmaceutical pricing and reimbursement pressures may negatively impact our sales.
  • Our manufacturing strategy exposes us to significant risks.
  • We rely in part on third parties to perform activities that are critical to our business.
  • Reports of actual or perceived side effects and other adverse effects associated with our products could cause our sales to decrease or regulatory approvals to be revoked.
  • Negative attention from special interest groups may impair our business.
  • We may not maintain adequate insurance coverage to protect us against significant product liability claims.
  • If we fail to attract and retain key management and qualified scientific and technical personnel, we may not be able to achieve our business objectives.
  • We must comply with extensive laws and regulations in the United States and other countries. Failure to obtain approvals on a timely basis or to comply with these requirements could delay, disrupt, or prevent commercialization of our products.
  • Regulatory approval for our currently marketed products is limited by the FDA and other regulators to those specific indications and conditions for which clinical safety and efficacy have been demonstrated.
The other 20 risks
  • We must comply with various laws in jurisdictions around the world that restrict certain marketing practices.
  • Government healthcare reform and other reforms could adversely affect our revenue, costs, and results of operations.
  • If we fail to comply with our reporting and payment obligations under the Medicaid Drug Rebate program or other governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions, and fines, which could adversely impact our business, financial condition, results of operations, and prospects.
  • We may be subject to enforcement action or penalties in connection with the contract pharmacy policy we have implemented pursuant to the 340B program.
  • Patient assistance programs for pharmaceutical products have come under increasing scrutiny by governments, legislative bodies, enforcement agencies, and other third parties. These activities may result in actions that effectively reduce prices or demand for our products, harm our business or reputation, or subject us to fines or penalties.
  • Improper handling of hazardous materials used in our activities could expose us to significant remediation liabilities.
  • The increasing use of social media platforms and artificial intelligence-based software presents new risks and challenges.
  • If any of the agreements under which we license or acquired intellectual property rights are breached or terminated, we could lose our rights to continue to develop, manufacture, and sell the products covered by such agreements.
  • Our intellectual property rights may not effectively deter competitors from developing competing products that, if successful, could have a material adverse effect on our revenues and profits.
  • Third parties have alleged, and may in the future allege, that our products or services infringe their patents and other intellectual property rights, which could result in the payment of royalties that negatively affect our profits, subject us to costly and time-consuming litigation, or cause us to lose the ability to sell the related products.
  • Cybersecurity incidents and other disruptions impacting our networks, systems, or data may have a material adverse effect on our business.
  • If we need additional financing and cannot obtain it, our product development and sales efforts may be limited.
  • Our portfolio of investments is subject to market, interest, operational, and credit risk that may reduce its value.
  • If we are not able to successfully identify, finance, consummate, and/or integrate acquisitions, our business operations and financial position could be adversely affected.
  • The price of our common stock can be highly volatile and may decline.
  • Provisions of Delaware law, our charter, bylaws and employment and license agreements, among other things, could prevent or delay a change of control or change in management that may be beneficial to our public shareholders.
  • Our shareholders must rely on stock appreciation for any return on their investment in us.
  • Our exclusive forum bylaw may limit our shareholders’ ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers, or other employees.
  • In 2021, we converted to a Delaware PBC. Conversion may not result in the benefits that we anticipate, requires our directors to balance the interest of shareholders with other interests, and may subject us to additional litigation and other risks.
  • As a Delaware PBC, we may be subject to increased litigation risk.

Legal proceedings

Currently, and from time to time, we are subject to claims in legal proceedings arising in the normal course of business. While we presently believe that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm our financial position, cash flows, or results of operations, legal proceedings are inherently uncertain, and unfavorable rulings could, individually or in the aggregate, have a material adverse effect on our business, financial condition, or operating results. See Note 14—Litigation, to our consolidated financial statements, which is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
    SEC EDGAROther events
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
    SEC EDGAROther events
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69